Market Overview

UPDATE: Canaccord Genuity Reiterates Cepheid at Buy with $50 PT Post Analyst Day

Related CPHD
Cepheid Announces Diagnostic Collaboration With MedImmune And COMBACTE To Facilitate Clinical Trials Of New Monoclonal Antibodies To Prevent Serious Infectious Diseases
Benzinga's Top Upgrades
Cepheid promotes COO to President (Seeking Alpha)

Canaccord Genuity maintained its Buy rating and $50 price target on Cepheid (NASDAQ: CPHD).

Canaccord Genuity noted, "We reiterate our BUY rating and $50 price target on CPHD given its solid 20% revenue growth, large customer base (approaching 3,000), and an unmatched test menu (11 FDA approved assays). Cepheid's analyst day provided an update to investors on its long-term financial targets, competitive advantages, and future products. However, due to three consecutive missed quarters, no EPS visibility, and lengthening selling cycles, CPHD shares experienced a pullback."

Cepheid closed at $35.18 on Thursday.

Latest Ratings for CPHD

Feb 2016Stifel NicolausMaintainsBuy
Feb 2016BairdMaintainsOutperform
Jan 2016Avondale PartnersInitiates Coverage onMarket Outperform

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Reiteration Intraday Update Analyst Ratings


Related Articles (CPHD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters